Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer.
By Zhibin Hu, X. Chen, Yang Zhao, T. Tian, G. Jin, Yongqian Shu, Yijiang Chen, Lin Xu, Ke Zen, Chenyu Zhang and 1 more. Journal of Clinical Oncology, 2010
809 citations recorded by the source corpus.
Subfields: Cancer Research, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/6618910e60a7a3f4933078b2ea1dfcf90cec59cc
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Molecular Biology
Citations in the corpus
- Cell-free nucleic acids as biomarkers in cancer patients (2011, background): “, and in non-small-cell lung cancer (NSCLC) serum miRNA levels were found to be altered more than fivefold between patients with longer and shorter surviva”
- Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies (2011, background): “themiRNAbiomarkerswe examined,weobserved variation attributable to blood cell effects that was greater in magnitude thanmanyof the differences reported betweenpatients with cancer and controls (13, 15, 20).”
- MicroRNAs in body fluids—the mix of hormones and biomarkers (2011, neutral): “Another study in NSCLC demonstrated that a set of 11 serum miRNAs were differentially expressed between patients with longer or shorter survival, and among this set, four ( miR-486 , miR-30d , miR-1 , and miR-499 ) were associated with decreased overall survival of patients”
- Exosome and Exosomal MicroRNA: Trafficking, Sorting, and Function (2015, background): “Accumulating evidence has shown that miRNAs can stably exist in body fluids, including saliva [11,12], urine [13], breast milk [14], and blood [11,15,16].”